NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036

PUBT · 2d ago
NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036
  • NewcelX received a Brazilian patent covering its cell selection and enrichment manufacturing process for NCEL-101 in type 1 diabetes.
  • Patent BR 112018010946-0 runs to November 2036, extending IP coverage in a large Latin American diabetes market.
  • The program is moving toward clinical trials following an FDA Type B Pre-IND meeting for NCEL-101 with Eledon’s anti-CD40L antibody tegoprubart.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150900PRIMZONEFULLFEED9762671) on July 15, 2026, and is solely responsible for the information contained therein.